What Actually Helps Menopause Joint Pain

Talk to your doctor or another healthcare provider before starting any new supplement or changing any treatment, especially if you are pregnant, taking medication, or managing a health condition.

You've read the list. Move more, sleep better, ask about hormones, maybe try collagen. All of the top three search results for this question gave a version of it. None said how much any of it helped, or in whom. If someone has also told you it's just age, the case against that is here, along with how to tell this from arthritis.

Here is the finding that governs everything below: in what we read, almost nothing on the list has been properly tested on joint pain in natural menopause. For perimenopause specifically, we found close to nothing. Most of what follows comes from women with osteoarthritis, women on breast cancer drugs, or trials that weren't designed to answer this question. You should know whose results you're borrowing.

We sell turmeric, and our own ingredient gets the same treatment as everything else.

The short answer

"How sure" is our own read of the evidence, not a grade from the studies. Each section below links the sources.

If you want a place to start, we'd start with movement. That's a judgment call, not a measurement. It needs no prescription, and the rheumatologist's review cited below recommends resistance work for muscle and bone as well as joints. Nothing here shows it beats anything else on this table.

Three terms will help with the rest.

Randomized trial vs association. In a randomized trial, chance decides who gets the treatment, so a difference between groups is more likely to come from it. An association only means two things travel together.

Clinically important difference. The smallest change researchers think a person would notice or care about. A result can pass the statistics and still fall short of it.

Borrowed evidence. A result in women with osteoarthritis, or women on aromatase inhibitors (a breast cancer drug that can cause joint pain), might carry over to you. It might not, because the pain may have a different cause.

Movement and strength

The evidence here is more modest than the lists imply. The closest trial we found is a disappointing one. Munukka and colleagues put 87 postmenopausal women aged 60 to 68 with mild knee osteoarthritis through four months of resistance training in water. Stiffness improved by 8.5 mm, and that gain was gone at 12 months. Pain, function and quality of life didn't change. It was a secondary analysis, and mild disease may have left little room to improve (our read, not the authors').

The strongest result on joint pain comes from a different group. Irwin and colleagues randomized 121 previously inactive breast cancer survivors with joint pain from aromatase inhibitors. A year of aerobic exercise (150 minutes a week) plus two weekly supervised strength sessions took worst joint pain down 1.6 points (29%), against a rise of 0.2 points (3%) with usual care. There was no placebo, and this is cancer-drug joint pain, not natural menopause.

Cochrane's 2024 review of knee osteoarthritis, 139 trials and 12,468 people, put exercise 8.7 points better than attention control on a 0 to 100 pain scale, with low certainty, and 13.14 points better than usual care. The smallest difference it counted as important was 12 points, so the first figure falls short and the second isn't clearly meaningful. It also found low-certainty evidence that exercise may increase adverse events. The American College of Rheumatology guideline strongly recommends exercise for knee, hip and hand osteoarthritis anyway. A strong recommendation and a modest effect can both be true.

The most useful finding may be that, in the knee review, no type of exercise beat another. So if a page says one form is the answer, ask to see the trial. For menopause specifically, rheumatologist Dr. Manno, writing in Menopause in March 2026, recommends progressive resistance exercise, meaning the load goes up over time, and suggests a physical therapy referral if you're new to it. That's clinical guidance rather than a trial result. Our read: choose what you'll keep doing, and make some of it strength work.

Hormone therapy

This is probably what you're weighing, and the evidence points in more than one direction.

Estrogen alone. In the Women's Health Initiative, 10,739 postmenopausal women who had already had a hysterectomy took oral conjugated equine estrogens (0.625 mg a day) or a placebo. After a year, 76.3% on estrogen reported joint pain, against 79.2% on placebo. That's real, and it's about three percentage points. Joint swelling went the other way, 42.1% on estrogen and 39.7% on placebo. That gap shrank after adjusting for adherence. In a subset followed to year 6, swelling stayed more common on estrogen, though the change in severity was no longer significant.

Estrogen plus progestin. In the companion trial of 16,608 women with an intact uterus, average age 63, relief of joint pain or stiffness at one year was reported by 47.1% on treatment and 38.4% on placebo. That's nearly nine percentage points, and new musculoskeletal symptoms were less likely to start. It measures relief, in a different group of women, so it isn't a clean comparison with the estrogen figure. The same trial reported vaginal bleeding in 51% vs 5% at 6 months, and more new breast tenderness (9.3% vs 2.4%).

The pooled answer points the other way, and it asks something else. A March 2026 meta-analysis combined 57 studies and nearly 4 million participants and compared ever using hormone therapy with never using it. The risk ratio for generalized musculoskeletal pain was 1.00, meaning no difference (95% CI 0.96 to 1.04). Its authors report substantial variation across studies and call for purpose-built ones. Ever vs never isn't the same test as a randomized comparison at one year, so it doesn't cancel the trials, and the trials don't cancel it. We can't resolve that for you, and we'd distrust anyone who says they can.

The estrogen analysis was post hoc, joints weren't its main endpoint, and its authors say the scales weren't validated. Women in both trials were postmenopausal and enrolled between 50 and 79, so they say little about perimenopause. We didn't find joint-pain evidence on modern regimens such as patches or micronized progesterone.

The guidance sits in between. The Menopause Society's 2022 position statement says women in these studies "have less joint pain or stiffness with hormone therapy compared with placebo", and doesn't list joint pain as an indication. Dr. Manno is blunter: "There are no large randomized, controlled trials looking specifically at hormone therapy as a treatment for joint pain during menopause." Manno says it "may play a therapeutic role" and is worth considering "when clinically appropriate".

The FDA changed the labeling in February 2026, removing cardiovascular, breast cancer and probable dementia statements from the boxed warning, starting with six products. Joint pain isn't among the uses it lists. A label change doesn't make hormone therapy risk-free, and your own history still decides this.

If hot flashes or bone are already on the table, joints may be a useful extra point in that conversation. If joints are your only reason, these are the sizes to bring to your doctor.

Sleep

We didn't find a trial of sleep treatment with a joint-pain endpoint in menopausal women. Everything here is indirect.

The nearest test of whether fixing sleep helps pain is a trial in 327 adults aged 60 and over with osteoarthritis pain, about three-quarters of them women, using telephone cognitive behavioral therapy for insomnia (a structured, drug-free program). The insomnia benefit lasted 12 months. The pain improvement had faded by then.

If your sleep is bad, treat it for its own sake and ask your doctor about this therapy. Whether your joints follow is unknown.

Weight, and a word on diet

This only applies if you're carrying extra weight.

We didn't find a weight-loss trial with a joint-pain endpoint in menopausal women. The nearest evidence is in knee osteoarthritis. The IDEA trial followed 454 overweight or obese adults aged 55 and over, 72% of them women, for 18 months. The group on diet plus exercise lost 10.6 kg (11.4%) and ended with pain of 3.6 on a 0 to 20 scale, against 4.7 with exercise alone. The ACR guideline strongly recommends weight loss for knee or hip osteoarthritis with overweight or obesity, and says losing 5% or more can change outcomes.

All three pages we read mention diet. We didn't find a trial on menopausal joint pain to report.

Pain relievers

For osteoarthritis, the ACR guideline strongly recommends oral NSAIDs such as ibuprofen for knee, hip and hand, and topical NSAIDs for the knee. For menopause joint pain, Dr. Manno says only that NSAIDs may give some relief, and that there is "no role for corticosteroids or immunosuppressive agents" to treat it. That line is about menopause joint pain, not diagnosed inflammatory arthritis.

We didn't review NSAID safety, so don't read our silence as reassurance. If you're using them for more than the occasional bad day, talk to your doctor or pharmacist about long-term use.

Supplements, including the ingredient we sell

Weigh this section knowing we sell turmeric. We aren't recommending curcumin, its main active compound. What follows is what the trials reported, not our claim about what it does.

The most direct trial we found. Shabani and colleagues (BMJ Open, September 2025) ran a double-blind, placebo-controlled trial at two clinics in Tabriz, Iran, enrolling 74 women aged 40 to 60 who had been through natural menopause at least a year, and 33 and 31 finished. The curcumin group took 500 mg twice a day for 8 weeks, which is what the trial used and not a suggested dose. They scored 5.3 points better than placebo on the MSK-HQ, a 0 to 56 musculoskeletal health questionnaire (95% CI 3.3 to 7.4, p<0.001). The published clinically important difference for that questionnaire is 5.5. So the result passed the statistics and just missed the line, with a range that runs either side of it.

The MSK-HQ is broad, covering pain, function, sleep, mood and self-management, so it isn't specific to joint pain. The women weren't selected for joint pain, though 97 to 100% reported muscle pain. They were a convenience sample, results were self-reported, and it ran 8 weeks in one city. The paper also has reporting errors, including a table headed 48 women per arm when 37 were enrolled.

The pilot. Lustberg and colleagues (2024) tested 200 mg a day of nanoemulsion curcumin against placebo for 3 months in women on aromatase inhibitors, with 42 randomized and 34 evaluable. Its main goal was feasibility, and its authors say it was "not powered to test for efficacy". There was no significant difference in pain severity (−1.5 vs −1.4, p=0.88). On FACT-ES, a broad well-being and endocrine-symptom questionnaire, placebo scored higher (p=0.039), a figure the authors note wasn't adjusted for multiple tests. They also describe non-significant trends toward curcumin on a pain subscore and grip strength.

The review. Akyakar and colleagues (2025) went through 12 randomized trials in postmenopausal women and found "no significant effects on physical, psychological, or sexual functions", concluding that efficacy for menopause symptoms "cannot be conclusively established". Its only joint-relevant trial is the Lustberg pilot. The Shabani trial isn't in it.

That leaves an open question: one small positive trial on a broad questionnaire, one pilot that couldn't test efficacy and leaned the wrong way on its broadest measure, and one review that doesn't include the positive trial. We won't round that up because we sell the ingredient, or round it down to look virtuous.

Vitamin D and omega-3. In the VITAL trial, 1,398 US adults with chronic knee pain (66% women) took them for an average of 5.3 years. Neither had any effect on pain, function or stiffness. It wasn't a menopause trial and didn't select people low in vitamin D.

Glucosamine. The ACR guideline strongly recommends against it for knee, hip and hand osteoarthritis, and raises concern about industry-funded results differing from public ones.

Collagen. A review of 25 trials and 2,856 patients with osteoarthritis reported a small-to-moderate improvement in pain (standardized difference −0.35, moderate certainty), and its authors call the evidence strong. A second review of 11 knee osteoarthritis trials also favored collagen, with pain results that varied widely between trials (I² of 88%). We found no collagen trial in menopausal joint pain.

Safety. "Natural" doesn't settle anything here. A US liver-injury network reported 10 turmeric-associated cases from 2004 to 2022: 8 were women, median age 56, 5 were hospitalized and 1 died. Its authors say this injury appears to be increasing in the US, perhaps reflecting usage patterns or more combination with black pepper. A case series like this can't tell you how often it happens, only that it does. In the Shabani trial, the authors called their sample insufficient for safety conclusions, and they excluded women on anticoagulants. If you take any medication, read what to check about turmeric and your medications first.

When to push for a rheumatologist, and how

Assuming everything is menopause can mean treatable arthritis gets missed. Menopause joint pain, as Dr. Manno describes it, usually involves several joints "without obvious swelling", and no blood test confirms it. Manno names these signs as pointing toward inflammatory arthritis or another condition:

• Striking morning stiffness
• Joint swelling or warmth
• Trouble in the hands or wrists, which should raise the question of rheumatoid arthritis
• Skin changes, Raynaud's (fingers that change color in the cold), a cough, low blood counts, or marked weakness in the shoulders and hips

Manno also says to rule out osteoarthritis, statins and other medications, thyroid problems and low vitamin D.

Normal blood tests don't end this. UK guidance from NICE says to refer any adult with suspected persistent joint inflammation of unknown cause. It says to refer urgently, even with normal inflammation markers or negative antibody tests, if any of these apply: small joints of the hands or feet are involved, more than one joint is affected, or three months or more passed between symptoms starting and seeking medical advice. That's UK guidance and we didn't open a US equivalent, but the reasoning is useful at any appointment.

Here's a script you could adapt. It's our suggestion, not a clinical protocol.

"My joints have been [painful / stiff / swollen] for [how long]. It's mainly [which joints]. Morning stiffness lasts about [timed minutes]. I've seen [swelling or warmth, and where].

I know menopause could explain some of this. Before we settle on that, I'd like to rule out inflammatory arthritis, and I'd like a referral to a rheumatologist.

If my blood tests come back normal, I'd still like to discuss the referral, because I understand normal results don't always settle it. If you don't think I need one, can you tell me why and note it in my chart?"

What to do next

Start strength work you can keep up, if you can, and raise the load over time. Before your next appointment, time your morning stiffness for a week, note which joints hurt and whether any swell, and write down everything you take, supplements included. Then ask your doctor two questions: does anything here need a rheumatologist, and given your history, do these hormone therapy numbers change anything for you?